Thyrocare bonus shares explained: price dip expected after 2:1 issue
Thyrocare bonus shares explained: price dip expected after 2:1 issue
Thyrocare Technologies' board approves a 2:1 bonus, boosting shares while triggering an optical price fall as the market adjusts. Here's what investors should know about the Rs 106.11 crore move.
Thyrocare Technologies Ltd has approved an increase in its authorised share capital and a 2:1 bonus issue for shareholders. Under the plan, two additional shares will be issued for every one held, taking a investor’s total to three shares. The ex-bonus trading day is expected to be Friday, with the stock price likely to adjust downward to reflect the higher share count. Previously, the stock settled around Rs 1,472 per share on Thursday, and the opening price today may show a sharp fall—a move that is largely optical rather than indicative of weaker fundamentals. The market adjustment occurs because more shares are now in circulation, so the price per share is expected to drop proportionally while the overall value of a shareholder’s stake remains the same.
The company has stated that the bonus issue will be funded by capitalising amounts from the capital redemption reserve and/or securities premium account, and/or free reserves or retained earnings. In tandem with the bonus, Thyrocare’s board approved a significant increase in the authorised share capital from Rs 100 crore (divided into 10 crore equity shares of Rs 10 each) to Rs 300 crore (divided into 30 crore equity shares of Rs 10 each), requiring an alteration in the capital clause of the Memorandum of Association subject to shareholder and regulatory approvals. Before the bonus, the issued, subscribed, and paid-up capital stood at Rs 53,05,38,970, comprising 5,30,53,897 shares of Rs 10 each. The new structure will adjust the capital framework to accommodate the larger share base.
Bonus issues like this can change the stock’s immediate price without diluting ownership in the long run, provided the company’s underlying fundamentals stay intact. While the price shows a decline at the outset, the total value held by investors who do not trade may remain unchanged as the bonus shares are issued from reserves and retained earnings rather than from new money. For Thyrocare, the next steps involve regulatory clearances and the practical implementation of the share-capital restructuring, along with ongoing monitoring of how the market digests the enlarged equity base. Investors should watch for further updates on the regulatory approvals and any commentary on the company’s earnings trajectory post-bonus.
Cover image source: Thyrocare Technologies bonus shares explained: Why stock price may see steep fall today 🔗
